MA
SNDX icon

MCF Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

MCF Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-38,000
Closed -$334K – 486
2019
Q4 		$334K Hold
38,000
– – 0.05% 112
2019
Q3 		$284K Hold
38,000
– – 0.05% 121
2019
Q2 		$354K Hold
38,000
– – 0.06% 101
2019
Q1 		$200K Hold
38,000
– – 0.03% 138
2018
Q4 		$169K Buy
+38,000
New +$208K 0.03% 139

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

MCF Advisors's SNDX Position: Q1 2020 in Review

MCF Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q1 2020, closing a stake of 38,000 shares — an estimated $334K sold.

MCF Advisors first reported a position in SNDX in Q4 2018 and held it in 5 quarters. The position peaked at $354K in Q2 2019. 83 funds tracked by Wall St. Rank hold SNDX as of Q1 2020.

  • MCF Advisors reported no remaining Syndax Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • MCF Advisors sold 38,000 Syndax Pharmaceuticals shares in Q1 2020, an estimated $334K.
  • MCF Advisors first reported a position in Syndax Pharmaceuticals in Q4 2018 and held it in 5 quarters.
  • MCF Advisors's Syndax Pharmaceuticals position peaked at $354K in Q2 2019.
  • 83 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2020.

Based on MCF Advisors's 13F filing for Q1 2020, filed 24 Apr 2020.